Aurobindo’s Eugia Pharma Specialities subsidiary gets FDA OK for generic Vidaza

Aurobindo’s Eugia Pharma Specialities subsidiary has received the Food and Drug Administration’s permission for azacitidine for injection, 100 mg single-dose vial, which is the generic of Bristol-Myers Squibb’s Vidaza.

Generic Vidaza is expected to be launched by this month. It is indicated for the treatment of adult patients with the following FAB myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions); refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; and chronic myelomonocytic leukemia.

[Read more: Aurobindo Pharma continues injectable business restructuring]

The medication had an estimated market size of roughly $46 million for the 12 months ending November 2022, according to IQVIA.